Kanwal Raghav, MD, discusses the results of a Phase 2 trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma.
Dr. Raghav is an Associate Professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
About the Trial
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab was tested in a Phase 2 clinical trial for patients with malignant peritoneal mesothelioma. Bevacizumab is an agent that blocks growth of new blood vessels. Therefore limiting the supply of oxygen to the tumor.
The study — A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma — enrolled 20 patients, of which 7 responded to treatment. The 1-year overall survival was 79%. At 1-year, in 59% of patients’ disease didn’t progress. Hypertension and anemia were two most common adverse events.
Peritoneal mesothelioma occurs in 10% to 15% of all mesothelioma cases. As a result, research into this type of mesothelioma is extremely rare.
Watch MesoTV
MesoTV and all of its informational videos are possible with the generous support of our donors and sponsors. Importantly, during this difficult time we are able to continue serving, informing, and educating the mesothelioma community. Please take note of our Season 2 sponsors at the beginning of the video: Merck; The Gori Law Firm; Early, Lucarelli, Sweeney & Meisenkothen; and AstraZeneca.
Don’t miss any of our new videos – sign up to receive our news or subscribe to our YouTube Channel by pressing the red “Subscribe” button.
MesoTV is the Mesothelioma Applied Research Foundation’s recorded video series covering pertinent conversations impacting the mesothelioma community. You can learn more at curemeso.org/mesotv.
